{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:39Z","timestamp":1740107439338,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00280-023-04540-9","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T10:02:01Z","timestamp":1684404121000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma"],"prefix":"10.1007","volume":"92","author":[{"given":"Katelyn N.","family":"Purvis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope D.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar Kulldeep","family":"Niloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Panetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine R.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-9355","authenticated-orcid":false,"given":"Jamie E.","family":"Flerlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"issue":"26","key":"4540_CR1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMp1212468","volume":"367","author":"ML Metzger","year":"2012","unstructured":"Metzger ML, Billett A, Link MP (2012) The impact of drug shortages on children with cancer\u2013the example of mechlorethamine. N Engl J Med 367(26):2461\u20132463","journal-title":"N Engl J Med"},{"issue":"26","key":"4540_CR2","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML et al (2022) Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 386(26):2482\u20132494","journal-title":"N Engl J Med"},{"issue":"2","key":"4540_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","volume":"6","author":"LH Sehn","year":"2022","unstructured":"Sehn LH et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6(2):533\u2013543","journal-title":"Blood Adv"},{"issue":"25","key":"4540_CR4","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P et al (2020) ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 38(25):2849\u20132861","journal-title":"J Clin Oncol"},{"issue":"9","key":"4540_CR5","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27(9):1492\u20131501","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"4540_CR6","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminhematol.2011.03.002","volume":"48","author":"LM Leoni","year":"2011","unstructured":"Leoni LM (2011) Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 48(Suppl 1):S4-11","journal-title":"Semin Hematol"},{"issue":"11","key":"4540_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1517\/17425255.2012.723690","volume":"8","author":"A Korycka-Wolowiec","year":"2012","unstructured":"Korycka-Wolowiec A, Robak T (2012) Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opin Drug Metab Toxicol 8(11):1455\u20131468","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"4540_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00280-010-1254-8","volume":"66","author":"JS Owen","year":"2010","unstructured":"Owen JS et al (2010) Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin\u2019s lymphoma. Cancer Chemother Pharmacol 66(6):1039\u20131049","journal-title":"Cancer Chemother Pharmacol"},{"key":"4540_CR9","unstructured":"Moon Y, E J, Garnett C, et al (2011) Clinical Pharmacology Review Document. https:\/\/www.022405orig1s000clinpharmr.pdf (fda.gov)"},{"issue":"12","key":"4540_CR10","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/cncr.33465","volume":"127","author":"S Jeha","year":"2021","unstructured":"Jeha S et al (2021) Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer 127(12):2074\u20132082","journal-title":"Cancer"},{"key":"4540_CR11","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/22249s000_MedR_P1.pdf."},{"issue":"4","key":"4540_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz AJ et al (2013) Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 31(4):456\u2013460","journal-title":"J Clin Oncol"},{"issue":"15","key":"4540_CR13","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1200\/jco.2012.30.15_suppl.9502","volume":"30","author":"M Metzger","year":"2012","unstructured":"Metzger M, Stanford V et al (2012) chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma results of a multi-institutional prospective clinical trial. J Clin Oncol 30(15):9502\u20139502","journal-title":"J Clin Oncol"},{"issue":"11","key":"4540_CR14","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/sj.bjc.6603776","volume":"96","author":"M Rasschaert","year":"2007","unstructured":"Rasschaert M et al (2007) A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. Br J Cancer 96(11):1692\u20131698","journal-title":"Br J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04540-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T11:04:53Z","timestamp":1686567893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4540"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04540-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bendamustine was received from TEVA pharmaceuticals in support of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}